Continuity of Methods: Characterizing Protein Therapeutic Stability From Developability Assessment to Release With Aura PTx

BPI Contributor

March 14, 2022

20 Min View
Continuity of Methods: Characterizing Protein Therapeutic Stability From Developability Assessment to Release With Aura PTx

Date: Mar 14, 2022

Duration: 20 Min

Already have an account?

This webcast features: Bernardo Cordovez, CSO, Co-Founder, Halo Labs.

Aura PTx is a complete protein therapeutic stability solution that enables characterization of subvisible particle aggregates from developability assessment through product release. Aura PTx is a high throughput analytical instrument that images, counts, sizes, and identifies subvisible particle aggregates, a critical quality attribute and the most important biologic stability parameter. Using volumes as low as 10 µL and with measurements of one minute per sample, Aura PTx enables rapid, highly contrast and thorough subvisible particle screening and absolute particle quantification.

In addition, it is powered by fluorescence membrane microscopy, a proprietary technique than enables individual particle identification analysis, which is helpful to identify and segment particles as protein aggregates, degraded polysorbate particles and other particulate impurities relevant to protein therapeutic development.

In this talk, we overview ability to perform subvisible particle analysis from cell line development through developability assessment, into product development and release as it is USP 1788 Method 2 compliant.

Just fill out the form below to watch the recorded webcast now.

You May Also Like